معرفی
Johan Wannberg is a Researcher at Uppsala University's Department of Medicinal Chemistry within the Preparative Medicinal Chemistry division. His work is closely associated with SciLifeLab, reflecting interdisciplinary collaboration in drug discovery. Affiliated with Uppsala Biomedicinska Centrum (BMC), he maintains active research in medicinal chemistry with significant contributions to pharmaceutical science.
Dr. Wannberg's research focuses on angiotensin receptor ligands, particularly AT2R antagonists for pain management, and cancer therapeutics targeting enzymes like MTHFD2 in leukemia. His expertise extends to antiviral development against HIV and SARS-CoV-2, utilizing microwave-assisted synthesis and DNA-encoded libraries for efficient compound discovery. Key areas include protease inhibition, receptor pharmacology, and metabolic pathway targeting.
His publication trend shows a strategic evolution from HIV protease inhibitors (2006-2010) to cancer metabolism (2022) and pandemic-responsive virology (2024), consistently leveraging advanced synthetic methodologies. Recent work emphasizes high-affinity AT2 receptor ligands (2021-2024) and innovative techniques like continuous-flow microwave chemistry.
Scientific recognition includes patent citations across multiple publications, with significant Mendeley readership (up to 90 readers) and social media engagement (54+ X users) for his work on protease inhibitors and angiotensin targets.
Dr. Wannberg actively collaborates with research groups at Uppsala University and SciLifeLab, focusing on translational drug discovery. His methodology expertise in microwave synthesis and flow chemistry supports pharmaceutical development pipelines, particularly for challenging targets requiring precise stereochemical control and metabolic stability.
